Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
City University, London Imperial College London |
---|---|
Information provided by: | City University, London |
ClinicalTrials.gov Identifier: | NCT00274664 |
Amblyopia (‘lazy eye’) is the commonest visual disorder of childhood and is caused by an interruption to visual development. Occlusion of the better eye by patching is the mainstay of treatment, so forcing use, of the affected eye. We have little understanding of how much treatment is required for improvement, so occlusion may continue for many months. This is both demanding for the child and family as a whole. Treatment outcome is frequently unsatisfactory. Compliance is often poor, thus we do not know precisely how much treatment the child actually receives or how much is required.
To overcome this, we have designed an instrument that permits us to measure occlusion: an occlusion dose monitor (ODM) which provides an objective record of how much occlusion a child actually receives. Recently we have observed that 75% of improvement induced by occlusion occurs in the first four weeks of treatment. In this study we explore the possibility that by intensive treatment the period of amblyopia therapy can be shortened – i.e. treatment will be more efficient, more effective, and more ‘family-friendly’. The study hypothesis is that 12 hours/day of patching is more effective than 6 hours/day.
Condition | Intervention | Phase |
---|---|---|
Amblyopia |
Device: 6 hours occlusion by patching Device: 12 hours occlusion by patching |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study |
Official Title: | Randomised Occlusion Treatment of Amblyopia Study (ROTAS): Trial of Maximal Vs Substantial Doses of Occlusion to Evaluate Visual Outcome for Children With Amblyopia |
Estimated Enrollment: | 100 |
Study Start Date: | February 2002 |
Estimated Study Completion Date: | May 2005 |
The identification and subsequent management of amblyopia are major consumers of health service resource, and within the hospital sector account for around 80-90% of visits to the children’s eye service. Occlusion of the better eye is the mainstay of treatment and because we have little understanding of the dose-response relationship this may continue for many months and sometimes for many hundreds of hours. This is demanding for the child and family as a whole and yet the outcome is frequently unsatisfactory. Currently, there is no reliable data on the kinetics of visual improvement, so occlusion tends to be prescribed on an ad hoc basis. Recent pilot research has shown that 75% of the treatment-generated improvement occurs within the first 4 weeks when 6 hours/day occlusion is prescribed.
In this study we explore the possibility that by intensive treatment the period of amblyopia therapy can be shortened – i.e. made both more efficient and hopefully more effective. The purpose of the present study, the Randomized Occlusion Treatment of Amblyopia Study (ROTAS), is to compare two frequently employed patching regimens: ‘substantial’ (6 hrs/day) against ‘maximal’ (12 hrs/day) patching. Our experimental design incorporates objective occlusion monitoring and is able to discriminate the beneficial effect of refractive correction from that of occlusion. The study comprises three phases: ‘baseline’, ‘refractive adaptation’ and ‘occlusion.’ Our aim is to provide guidelines for patient management based, for the first time, on experimentally determined and statistically verifiable relationships between treatment and outcome.
Ages Eligible for Study: | 3 Years to 8 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom, Greater London | |
St Marys Hospitals | |
London, Greater London, United Kingdom, W2 1NY | |
United Kingdom, Middlesex | |
Hillingdon Hospital | |
London, Middlesex, United Kingdom, UB8 3NN |
Principal Investigator: | Merrick J Moseley, PhD | City University, London |
Study ID Numbers: | ROTAS-091206, Fight for Sight: 20500 |
Study First Received: | January 9, 2006 |
Last Updated: | January 9, 2006 |
ClinicalTrials.gov Identifier: | NCT00274664 |
Health Authority: | United Kingdom: National Health Service |
Amblyopia Occlusion dose monitoring Refractive adaptation Dose-response |
Signs and Symptoms Sensation Disorders Vision Disorders Amblyopia |
Eye Diseases Neurologic Manifestations Central Nervous System Diseases Brain Diseases |
Nervous System Diseases |